



More than any other tested health care industries, Americans think pharmaceutical companies are most responsible for the rising cost of health care.

- When thinking about the American health care system, of the tested options, a plurality of adults think pharmaceutical companies (39%) are *most responsible* for the rising cost of health care.
- Of the tested behaviors, a majority of Americans (57%) think brand-name pharmaceutical companies' anti-competitive tactics and price-gouging is most responsible for high prescription drug prices in the U.S. And this sentiment spans party lines:
 - A majority of Democrats (56%) and Republicans (61%) think brand name pharmaceutical companies' anti-competitive tactics and price-gouging is most responsible for high prescription drug prices.

Three in four Americans think PBMs play an important role in prescription drug pricing.

- And, of the tested options, only 3% of Americans think PBMs are most responsible for rising health care costs.

A plurality of Americans oppose the administration's proposed Rebate Rule.

- After being informed about the Rebate Rule and its projected impacts, Americans oppose rather than support the measure by a 28-point margin (45% vs 17%).

And, Americans are concerned about the potential impacts of the Rebate Rule.

- A strong majority of Americans (88%) express concern that the Rebate Rule could hike Medicare premiums for seniors and disabled Americans by as much as 40 percent.
- And, 88% of Americans express concern that big pharmaceutical companies are one of the most avid supporters of the Rebate Rule but say they cannot guarantee they will pass along the rebate savings to patients.

By a 68-point margin, Americans believe cracking down on the anti-competitive tactics and price-gouging of drug manufactures should be more of a focus of policymakers than eliminating rebates negotiated by PBMs

- After being informed that two-thirds of U.S. spending on pharmaceutical drugs went to pharmaceutical companies, four in five adults (84%) think it is most important policymakers focus on cracking down on anti-competitive and price-gouging tactics of drug manufactures rather than eliminating rebates negotiated by PBMs (16%).

Methodology:

This poll was conducted from May 21-23, 2019, among a national sample of 2,201 Adults. The interviews were conducted online and the data were weighted to approximate a target sample of Adults based on age, race/ethnicity, gender, educational attainment, and region. Results from the full survey have a margin of error of plus or minus 2 percentage points.